News | July 24, 2014

Brainlab Introduces New Concept for Treatment of Multiple Brain Metastases

Automatic brain metastases planning software could transform current treatment paradigms

Brainlab Introduces New Concept for Treatment of Multiple Brain Metastases

July 24, 2014 — Brainlab announced the release of its Elements automatic brain metastases planning software. The new software will simplify stereotactic radiosurgery (SRS) planning for metastatic brain tumors and is the newest addition to the Elements A La Carte software portfolio. It was showcased at the 2014 annual meeting of the American Association of Physicists in Medicine (AAPM) in Austin, Texas. The software is a work in progress and currently not for sale in the United States.

“When a patient develops more than one metastasis in the brain, one of the best treatment options available – radiosurgery – becomes impractical because the treatment time increases at the same rate as the number of metastases,” said Stefan Vilsmeier, president and CEO at Brainlab. “With our new technology, we are poised as a company to shift the treatment paradigm and provide more treatment options and a consistent way to deliver them.”

Brain metastases are the most common type of brain tumors, and the numbers continue to rise due to improved diagnostics and control of the primary disease. Whole-brain radiotherapy (WBRT) is still considered the standard of care; however it has been shown that WBRT can only prevent new tumors arising for a maximum of six months. There is clear recognition that not all patients with brain metastases have equivalently poor survival outcome, and a significant group lives for a longer period of time, prompting the debate regarding whether the patients in at least the best-prognosis category should be treated solely with more aggressive therapies upfront and keep WBRT as an option for later. Brainlab automatic brain metastases planning software brings to market technology that consistently and rapidly generates radiosurgery plans for the efficient treatment of multiple metastases.

“The [software] enables a ‘monitor-unit,’ and time-efficient treatment planning and delivery, while reducing the dose to healthy brain tissue,” said Niko Papanikolaou, Ph.D., chief medical physicist, University of Texas Health Science Center, San Antonio. “This novel approach to the treatment of metastatic brain tumors from Brainlab can potentially benefit several patients that are currently receiving whole-brain radiation. We can now plan and treat metastatic brain cancer, for patients with larger volumes and higher number of metastases without the anticipated association of a decline in neurocognitive function.”

Automatic brain metastases planning automatically selects a group of metastases in such a way that the multileaf collimator (MLC) fits to the shapes of these selected targets without leaving gaps. The algorithm generates an optimized volumetric conformal radiosurgery plan in a matter of minutes after all metastases have been outlined. With this new treatment concept, the software creates an optimized dose distribution no matter if one or ten metastases are being treated.

For more information: www.brainlab.com

Related Content

Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.